GLP-1 drugs, dual/triple agonists, and other peptide-based therapies are showing strong results in treating MASH (fatty liver disease), with multiple agents resolving liver inflammation and improving scarring in clinical trials.
MASH is now a leading cause of liver diseaseMultiple peptide-based therapies — including semaglutide, tirzepatide, and survodutide — are demonstrating the ability to resolve inflammation and improve fibrosis in clinical trials
What the researchers found
Multiple peptide-based therapies are showing substantial promise for treating MASH (metabolic dysfunction-associated steatohepatitis), the progressive form of fatty liver disease. GLP-1 agonists (semaglutide), dual agonists (tirzepatide, survodutide), and triple agonists are among the most advanced candidates. Recent trials demonstrate these drugs can resolve liver inflammation and improve fibrosis — the two key histological endpoints.
Other promising approaches include PPAR agonists (lanifibranor), FGF21 analogs (pegozafermin), THR-β agonists (resmetirom, the first FDA-approved MASH drug), and fatty acid synthase inhibitors. The field is moving toward combination therapies and precision medicine approaches using genetic variants like PNPLA3 to guide treatment selection.
Why it matters
MASH is now a leading cause of chronic liver disease globally, driven by the obesity and diabetes epidemics. Until recently there were no approved drugs for it. The emergence of incretin-based peptide therapies — many of them already approved for diabetes and obesity — represents a potential paradigm shift. These drugs could simultaneously treat patients' metabolic disease and their liver disease.
The numbers in context
Review covering semaglutide, tirzepatide, survodutide, lanifibranor, pegozafermin, resmetirom · MASH is leading cause of chronic liver disease · driven by obesity + T2D
How the study worked
Comprehensive narrative review published in the Journal of Clinical Investigation. The authors synthesize evidence from recent clinical trials of MASH therapeutics, regulatory developments, biomarker research, and emerging precision medicine approaches. The review covers drugs from Phase II through FDA approval.
Who was studied
Review of clinical trial and research literature on MASH therapeutics (no primary study population)
What this study cannot tell us
As a review, this presents no new data. The field is moving rapidly, so some information may become outdated quickly. The review focuses on pharmacological approaches and gives less attention to lifestyle interventions. Many of the promising agents discussed are still in clinical trials and may not succeed.
How to read the evidence
This is a review from a top-tier journal (Journal of Clinical Investigation) authored by leading MASH researchers. It synthesizes evidence from multiple Phase II/III trials and an FDA-approved drug. While it presents no new data, the quality of evidence reviewed is high.
When this study was published
Published in 2025. This is a very current review capturing the rapidly evolving MASH therapeutic landscape. Given the pace of drug development in this space, some specific trial results may have been updated since publication.
The bigger picture
MASH therapeutics is one of the hottest areas in drug development, with billions of dollars at stake. The convergence of GLP-1 drugs (already blockbusters for obesity), liver-targeted therapies, and precision medicine is creating an entirely new treatment paradigm. This review captures a pivotal moment: the transition from having no MASH drugs to having multiple promising candidates, many of them peptide-based, that address the metabolic root causes of the disease.
Questions still open
- Will combination therapies (e.g., GLP-1 agonist plus a PPAR agonist) outperform single agents for MASH?
- How long do patients need to stay on these drugs to maintain liver improvements, and what happens when they stop?
- Can genetic profiling (like PNPLA3 variants) reliably predict which patients will respond best to which therapy?
Common questions
What is MASH and why is it so dangerous?
Can GLP-1 drugs like semaglutide treat fatty liver disease?
Read the original research
Therapeutic horizons in metabolic dysfunction-associated steatohepatitis.
The Journal of clinical investigation, 135(13)
Citation
Newsome, Philip N; Loomba, Rohit. (2025). Therapeutic horizons in metabolic dysfunction-associated steatohepatitis.. The Journal of clinical investigation, 135(13). https://doi.org/10.1172/JCI186425